EMEA-002354-PIP02-18-M01
Key facts
| Invented name |
Brukinsa
|
| Active substance |
zanubrutinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0205/2022
|
| PIP number |
EMEA-002354-PIP02-18-M01
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
BeiGene Ireland Ltd.
E-mail: bg.ireland@beigene.com Tel. +353 15667660 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|